Compare Novartis with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs IPCA LABS - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS IPCA LABS NOVARTIS/
IPCA LABS
 
P/E (TTM) x 487.1 22.8 2,134.1% View Chart
P/BV x 28.3 4.4 638.3% View Chart
Dividend Yield % 1.6 0.1 1,526.1%  

Financials

 NOVARTIS   IPCA LABS
EQUITY SHARE DATA
    NOVARTIS
Mar-18
IPCA LABS
Mar-18
NOVARTIS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs758695 109.0%   
Low Rs579400 144.8%   
Sales per share (Unadj.) Rs228.4260.2 87.8%  
Earnings per share (Unadj.) Rs31.719.0 167.3%  
Cash flow per share (Unadj.) Rs32.833.1 99.1%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.50.2 819.3%  
Book value per share (Unadj.) Rs297.1213.0 139.5%  
Shares outstanding (eoy) m24.69126.20 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.1 139.1%   
Avg P/E ratio x21.128.9 73.0%  
P/CF ratio (eoy) x20.416.6 123.1%  
Price / Book Value ratio x2.22.6 87.5%  
Dividend payout %31.55.3 597.8%   
Avg Mkt Cap Rs m16,50569,120 23.9%   
No. of employees `0000.713.3 5.0%   
Total wages/salary Rs m1,4457,359 19.6%   
Avg. sales/employee Rs Th8,441.32,477.4 340.7%   
Avg. wages/employee Rs Th2,163.6555.2 389.7%   
Avg. net profit/employee Rs Th1,173.1180.6 649.4%   
INCOME DATA
Net Sales Rs m5,63932,836 17.2%  
Other income Rs m1,718418 411.1%   
Total revenues Rs m7,35733,254 22.1%   
Gross profit Rs m-634,505 -1.4%  
Depreciation Rs m251,777 1.4%   
Interest Rs m55240 23.0%   
Profit before tax Rs m1,5752,905 54.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792511 154.9%   
Profit after tax Rs m7842,394 32.7%  
Gross profit margin %-1.113.7 -8.1%  
Effective tax rate %50.317.6 285.7%   
Net profit margin %13.97.3 190.6%  
BALANCE SHEET DATA
Current assets Rs m9,52219,455 48.9%   
Current liabilities Rs m3,29610,076 32.7%   
Net working cap to sales %110.428.6 386.5%  
Current ratio x2.91.9 149.6%  
Inventory Days Days3798 37.4%  
Debtors Days Days2867 42.5%  
Net fixed assets Rs m4620,260 0.2%   
Share capital Rs m123252 48.9%   
"Free" reserves Rs m7,21326,633 27.1%   
Net worth Rs m7,33626,886 27.3%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m11,10541,173 27.0%  
Interest coverage x29.513.1 225.2%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.50.8 63.7%   
Return on assets %7.66.4 118.1%  
Return on equity %10.78.9 119.9%  
Return on capital %22.210.8 206.5%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m6115,642 0.4%   
Fx outflow Rs m3,6304,884 74.3%   
Net fx Rs m-3,57010,759 -33.2%   
CASH FLOW
From Operations Rs m1,6103,411 47.2%  
From Investments Rs m687-1,354 -50.7%  
From Financial Activity Rs m-2,677-1,304 205.2%  
Net Cashflow Rs m-380753 -50.4%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.4 17.5%  
FIIs % 1.6 25.3 6.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.4 123.6%  
Shareholders   41,647 36,892 112.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 13, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - JUBILANT LIFE SCIENCES COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS